Pressmeddelanden, rapporter och bolagsmeddelande för Raisio Oyj Vaihto-osake

Raisio Plc's interim report for July-September 2024 shows a 5.4% increase in net sales, reaching EUR 59.1 million. The company's comparable EBITDA was EUR 9.0 million, while EBITDA was EUR 8.1 million. Comparable EBIT stood at EUR 6.5 million, and EBIT was EUR 5.7 million. The cash flow from continuing operations after financial items and taxes was EUR 15.9 million. Earnings per share were EUR 0.03. For January-September 2024, net sales grew by 4.0% to EUR 172.0 million. Comparable EBITDA was EUR 25.7 million, and EBITDA was EUR 23.4 million. Comparable EBIT was EUR 18.2 million, and EBIT was EUR 16.0 million. Cash flow from continuing operations totaled EUR 32.1 million, with earnings per share at EUR 0.09. Raisio's market strategy is progressing, with a focus on growth and efficiency despite economic uncertainties. The company is preparing for increased regulation and upcoming brand anniversaries. Raisio projects its comparable EBIT for 2024 to be at or slightly above the 2023 level of EUR 22.7 million.

Raisio plc reported a manager's transaction involving Anna Haavisto, a closely associated person to Ilkka Haavisto, a member of the Supervisory Board. The transaction, dated July 22, 2024, involved the receipt of shares as a gift, donation, or inheritance. The transaction volume was 96,609 shares with a unit price of 0 EUR. Raisio plc, known for its plant-based and heart-healthy products, operates in over 40 markets and had a comparable net sales of EUR 219.5 million and EBIT of EUR 22.7 million in 2023. Raisio's shares are listed on Nasdaq Helsinki Ltd. For more information, contact Mika Saarinen, CFO, or Sari Koivulehto-Mäkitalo, CLO.

Raisio plc will release its Interim Report for January-September 2024 on November 5, 2024, at 8:30 am EET. The report will be available on their website. A Finnish-language webcast for analysts, investors, and media will be held by CEO Pasi Flinkman and CFO Mika Saarinen on the same day at 12:00 EET, with a recording available afterward. An English presentation will be posted on their website. Raisio is conducting a survey to improve financial and investor communications, with a deadline of November 8, 2024. Participants can enter a raffle for a Raisio product prize. Raisio focuses on creating plant-based and heart-healthy foods with brands like Benecol®, Härkis®, and Elovena®, and exports to over 40 markets. Their shares are listed on Nasdaq Helsinki Ltd. In 2023, Raisio's net sales were EUR 219.5 million, with an EBIT of EUR 22.7 million.

Raisio plc announced it will publish its Financial Statements Bulletin for 2024 on 13 February 2025 at 8:30 a.m. Finnish time. Additional financial documents, including the Financial Statement, Board of Directors' Report, Corporate Responsibility information, and Remuneration Report for 2024, will be released in week 11 of 2025. The 2025 financial report release dates are as follows: Interim Report for January−March on 13 May, Half-Year Financial Report for January−June on 12 August, and Interim Report for January−September on 11 November, all at 8:30 a.m. Finnish time. The Annual General Meeting is scheduled for 15 April 2025 in Turku, Finland, with the Board of Directors to summon the meeting later. Shareholders can request agenda items for the meeting by 17 February 2025. Raisio plc focuses on creating plant-based and heart-healthy food products, with brands like Benecol®, Härkis®, and Elovena®. The company operates in seven countries and exports to over 40 markets. In 2023, Raisio's comparable net sales were EUR 219.5 million, and comparable EBIT was EUR 22.7 million. Raisio's shares are listed on Nasdaq Helsinki Ltd.

Raisio plc's Half-Year Financial Report for January-June 2024 highlights a positive trend in their operating environment despite ongoing market challenges. The company reported increased sales volumes and net sales, with a nearly nine percent rise in the second quarter compared to the previous year, reaching EUR 57.3 million. Comparable EBIT grew by almost a third to EUR 7.4 million, or 13.0 percent of net sales. Investments in international growth, marketing, and product development were higher than the comparison period but were offset by higher sales and an improved gross margin. Key drivers of growth included strong performances of their brands, particularly Benecol® and Elovena®, with promising developments in main markets like the UK and Ireland. The company remains optimistic about the long-term potential of the plant protein market despite current challenges. Raisio projects its comparable EBIT for 2024 to be at or slightly above the 2023 level of EUR 22.7 million. The CEO expressed pride in the company's heritage and innovative capabilities. Further details on the financial report will be discussed in a webcast on August 7, 2024.